Related Experiment Video
Updated: May 30, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
Elizabeth Alli1, Vandana B Sharma, Anne-Renee Hartman
1Department of Medicine, Division of Oncology, Stanford University School of Medicine, Center for Clinical Sciences Research, Stanford, CA 94305, USA.
Background:
Breast cancers due to germline mutations or altered expression of the BRCA1 gene associate with an aggressive clinical course and frequently exhibit a "triple-negative" phenotype, i.e. lack of expression of the estrogen and progesterone hormone receptors and lack of overexpression of the HER2/NEU oncogene, thereby rendering them relatively insensitive to hormonal manipulation and targeted HER2 therapy, respectively. BRCA1 plays a role in multiple DNA repair pathways, and thus, when mutated, results in sensitivity to certain DNA damaging drugs.
Results:
Here, we used a Brca1 murine mammary epithelial cell (MMEC) model to examine the effect of loss of Brca1 on cellular sensitivity to various chemotherapy drugs. To explore novel therapeutic strategies, we included DNA damaging and non-DNA damaging drugs whose mechanisms are dependent and independent of DNA repair, respectively, and drugs that are used in standard and non-standard lines of therapy for breast cancer. To understand the cellular mechanism, we also determined the role that DNA repair plays in sensitivity to these drugs. We found that cisplatin and gemcitabine had the greatest specific therapeutic benefit to Brca1-deficient MMECs, and that when used in combination produced a synergistic effect. This sensitivity may be attributed in part to defective NER, which is one of the DNA repair pathways normally responsible for repairing DNA adducts produced by cisplatin and is shown in this study to be defective in Brca1-deficient MMECs. Brca1-deficient MMECs were not differentially sensitive to the standard breast cancer chemotherapy drugs doxorubicin, docetaxel or 5-FU.
Conclusions:
Both cisplatin and gemcitabine should be explored in clinical trials for first line regimens for BRCA1-associated and triple-negative breast cancer.
Insights
Cisplatin and gemcitabine show promise for treating BRCA1-associated triple-negative breast cancer. These DNA-damaging drugs offer a synergistic effect in Brca1-deficient cells, unlike standard therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRCA1 gene mutations are linked to aggressive triple-negative breast cancer (TNBC).
- TNBC lacks hormone receptors and HER2/NEU overexpression, limiting treatment options.
- BRCA1's role in DNA repair suggests sensitivity to DNA-damaging agents.
Purpose of the Study:
- To investigate the sensitivity of Brca1-deficient cells to various chemotherapy drugs.
- To explore novel therapeutic strategies for BRCA1-associated breast cancer.
- To elucidate the role of DNA repair in drug sensitivity.
Main Methods:
- Utilized a Brca1 murine mammary epithelial cell (MMEC) model.
- Tested sensitivity to DNA-damaging and non-DNA-damaging chemotherapy agents.
- Assessed the role of DNA repair pathways in cellular response.
Main Results:
- Cisplatin and gemcitabine demonstrated significant therapeutic benefit in Brca1-deficient MMECs.
- Combination therapy with cisplatin and gemcitabine yielded synergistic effects.
- Defective nucleotide excision repair (NER) in Brca1-deficient cells may explain cisplatin sensitivity.
- No differential sensitivity was observed with doxorubicin, docetaxel, or 5-FU.
Conclusions:
- Cisplatin and gemcitabine warrant clinical investigation for BRCA1-associated and triple-negative breast cancer.
- These agents could form effective first-line regimens for this patient subgroup.
